Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease - Trial NCT06099652
Access comprehensive clinical trial information for NCT06099652 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. and is currently Not yet recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Timeline & Enrollment
Phase 2
Nov 01, 2023
May 01, 2025
Primary Outcome
Change from baseline in pre-bronchodilator FEV1 at Week 16
Summary
The primary objective of the study was to evaluate the efficacy and safety of 611 in Chinese
 adults with moderate to severe COPD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099652
Non-Device Trial